Erythropoietin (EPO) primarily regulates red blood cell formation, and EPO serum levels are increased on hypoxic stress (e.g., anemia and altitude). In addition to anemia, recent discoveries suggest new therapeutic indications for EPO, unrelated to erythropoiesis. We investigated the skeletal role of EPO using several models of overexpression (Tg6 mice) and EPO administration (intermittent/continuous, high/low doses) in adult C57Bl6 female mice. Using microcomputed tomography, histology, and serum markers, we found that EPO induced a 32%-61% trabecular bone loss caused by increased bone resorption (+60%-88% osteoclast number) and reduced bone formation rate (219 to 274%; P < 0.05 throughout). EPO targeted the monocytic lineage by increasing the number of bone monocytes/macrophages, preosteoclasts, and mature osteoclasts. In contrast to the attenuated bone formation in vivo, EPO treatment in vitro did not inhibit osteoblast differentiation and activity, suggesting an indirect effect of EPO on osteoblasts. However, EPO had a direct effect on preosteoclasts by stimulating osteoclastogenesis in isolated cultures (+60%) via the Jak2 and PI3K pathways. In summary, our findings demonstrate that EPO negatively regulates bone mass and thus bears significant clinical implications for the potential management of patients with endogenously or therapeutically elevated EPO levels.-Hiram-Bab, S., Liron, T., Deshet-Unger, N., Mittelman, M., Gassmann, M., Rauner, M., Franke, K., Wielockx, B., Neumann, D., Gabet, Y. Erythropoietin directly stimulates osteoclast precursors and induces bone loss. FASEB J. 29, 1890-1900 (2015). www.fasebj.org
ERYTHROPOIETIN (EPO) IS BEST KNOWN for its function as an erythropoietic hormone secreted from the kidneys of adult mammals. The main trigger of EPO secretion is hypoxia, resulting from blood loss, anemia, or on exposure to high altitude. EPO binding to its cell surface receptor (EPO-R) results in downstream phosphorylation of the Janus kinase (JAK)/signal transducer and activator of transcription (STAT), PI3K/Akt, MAP kinase, and protein kinase C to facilitate the production of erythrocytes (1, 2) .
Recombinant human EPO (rHuEPO) is used in clinical practice for the treatment of several types of anemia, including anemia of end-stage renal disease (3) (4) (5) and chemotherapy-induced anemia (6) . It is also illegally administered as a performance-enhancing drug in athletes (7) . Unrelated to its primary erythropoietic function, EPO-R is expressed in diverse tissues including the brain, reproductive organs, placenta, heart, lungs, intestine, spleen, and bone (8) (9) (10) (11) (12) (13) . In line with these findings, new therapeutic indications of EPO were recently suggested for the management of nephropathies, ischemic injuries of several tissues such as intestine, pancreas, and myocardium, neuropathies, liver regeneration, adipose tissue inflammation, and diabetic retinopathy (10, (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) . Overall, the ubiquitous expression of EPO-R in nonerythroid cells associated with a plethora of nonhematopoietic functions has recently prompted the experimental evaluation of a vast array of potential future applications of EPO and its derivatives in the clinic.
In bone, osteoclasts are specialized cells derived from monocytes; they adhere to the bone matrix and secrete acid and lytic enzymes to resorb bone (23) . Monocyte differentiation into osteoclasts is driven by the receptor activator for nuclear factor kB (RANK)/RANK ligand (RANKL)/osteoprotegerin system, and M-CSF (24, 25) . Osteoblasts derived from mesenchymal stem cells are Abbreviations: ALP, alkaline phosphatase; BFR, bone formation rate; BSP, bone sialoprotein; BV/TV, bone volume/ total volume or trabecular bone fraction; Conn.D, connectivity density; mCT, microcomputed tomography; EPO, erythropoietin; EPO-R, erythropoietin receptor; FBS, fetal bovine serum; JAK, Janus kinase; MAR, mineral apposition rate;
(continued on next page) responsible for bone formation. A tight regulation between the osteoblastic and osteoclastic lineages is thus crucial for the control of bone turnover (26) . Evidence of a direct effect of EPO on bone metabolism is limited, and the few reports available are controversial. EPO was reported to support bone formation in fracture healing models (27) (28) (29) . Similarly, in newborn and growing mice, EPO administration increased bone mass by inducing bone formation (30) , but in contrast, EPO was shown to induce bone loss in adult mice (31, 32) . Thus, the exact role of EPO in bone metabolism and its mechanism of action remain to be elucidated.
In this work we tested the hypothesis that high EPO levels induce bone resorption in a model of high endogenous EPO levels (transgenic mice constitutively overexpressing human EPO) and in a therapeutic model (EPO-administered mice), via EPO-R signaling in the monocytic lineage. Our previous findings of EPO-Rs on macrophages (33) coupled to the fact that these cells are the precursors of osteoclasts directed particular emphasis to this cell lineage.
MATERIALS AND METHODS

Materials
All reagents were purchased from Sigma-Aldrich (St. Louis, MO, USA) unless otherwise specified. a-MEM, DMEM, and fetal bovine serum (FBS) were purchased from Rhenium (Modiin, Israel), and culture plates were from Corning (New York, NY, USA). As a source of M-CSF, we used supernatant from CMG 14-12 cells, containing 1.3 mg/ml M-CSF (25) . To inhibit cellular signaling pathways, we used LY294002 (Promega, Madison, WI, USA), U0126 (Cell Signaling, Danvers, MA, USA), and AG490 (Sigma-Aldrich).
Animals
All experiments were approved by the Institutional Animal Care and Use Committee of Tel Aviv University. This study was performed on female mice. Tg6 mice (34) bred on a pure C57BL/6J background were compared with their littermate controls at 12 weeks of age. In the experiment assessing the effect of low EPO doses, wild-type (WT) animals were injected with 30 U rHuEPO (Epoietin a, Eprex; Janssen-Cilag, High Wycombe, United Kingdom) or diluent (saline) for 10 consecutive days, followed by 3 injections/wk for 3 weeks (30U-inj). In another experiment, 180 U rHuEPO or diluent was injected 3 times/wk for 2.5 weeks (180U-inj). For continuous administration of EPO, we implanted Alzet osmotic pumps (Cupertino, CA, USA) releasing 7 U per day (or saline) for 10 days. These doses (30, 180, and 7 U per animal) correspond to 1500, 9000, and 350 U/kg, respectively.
Serum markers
At death, blood was collected, and levels of biochemical markers were measured in the serum. ELISA kit for tartrate-resistant acid phosphatase (TRAP)5b was purchased from Immuno Diagnostic Systems (Boldon, United Kingdom). The mouse osteocalcin detection kit was purchased from Biomedical Technologies (Ward Hill, MA, USA).
Microcomputed tomography
Femora (1 per mouse) were examined as reported previously (35, 36) using the microcomputed tomography (mCT) 50 system (Scanco Medical AG, Brüttisellen, Switzerland). Briefly, scans were performed at a 10 mm resolution. The mineralized tissues were segmented by a global thresholding procedure (37) . Trabecular bone parameters were measured in the secondary spongiosa of the distal femoral metaphysis, and cortical parameters were determined in the middiaphyseal region according to the standardized nomenclature (38) .
Histomorphometry
Mice were injected intraperitoneally with calcein 4 and 1 days before death to assess bone formation (35) . Following mCT, dynamic histomorphometric measurements and osteoclast TRAP staining were performed on undecalcified specimens as described previously (35) using Media Cybernetic ImagePro software (Rockville, MD, USA). The terminology and units used for these measurements were according to the 2012 convention of standardized nomenclature (39) .
Cell culture
Bone marrow cells were harvested from femurs and tibias of 8-to 12-week-old mice, and cells were seeded on tissue culturedtreated plates in standard medium (a-MEM, 10% FBS). On the following day, nonadherent cells were seeded in non-tissue culture-treated plates in standard medium supplemented with 100 ng/ml M-CSF, which induced differentiation into preosteoclasts. For the differentiation assay, preosteoclasts were plated in 96-well plates (6000 cells per well) with standard medium supplemented with 20 ng/ml M-CSF and 50 ng/ml RANKL (R&D Systems, Minneapolis, MN, USA), replaced every 2 days. On day 6, multinucleated osteoclasts were stained using a TRAP kit (Sigma-Aldrich), and relative TRAP-positive surface was measured using ImageJ software (National Institutes of Health, Bethesda, MD, USA). Pit resorption was performed as above on calcium phosphate-coated plates according to the manufacturer's instructions (CosmoBio, Tokyo, Japan). To calculate the resorbed area/osteoclasts area, a parallel experiment was carried out under the same conditions, namely, cells were seeded on a 48-well plastic plate (Greiner Bio-One, Monroe, NC, USA) in phenol-red free medium, with only one medium change on day 3. After 6 days, cells were removed, and micrographs were taken. Total area of resorbed pits was also measured using ImageJ software, and the pit area was divided by the osteoclast area. For the proliferation assay, preosteoclasts were plated with standard medium supplemented with 100 ng/ml M-CSF, and after 3 days, the number of viable cells was assessed using the thiazolyl blue tetrazolium bromide assay as previously described (33, 36) .
Calvarial osteoblasts cultures were prepared from 2-day-old pups as described previously (40) . To induce osteoblast differentiation, osteogenic medium containing ascorbic acid (50 mg/ml) and b-glycerophosphate (10 mM) was initiated at confluence, and alizarin red staining was performed at day 20 to measure mineralization.
(continued from previous page) MS/BS, mineralizing surface/bone surface; N.Oc/BS, osteoclast number/bone surface; OCN, osteocalcin; R, receptor; RANK, receptor activator of nuclear factor kB; RANKL, receptor activator of nuclear factor kB ligand; rHuEPO, recombinant human EPO; Tb.N, trabecular number; TRAP, tartrate-resistant acid phosphatase; WT, wild-type mRNA expression RNA from cells was extracted using an RNA purification kit (5 PRIME, Gaithersburg, MD, USA). cDNA was produced using the High Capacity cDNA Reverse Transcription Kit (Invitrogen, Grand Island, NY, USA), and real-time PCR was performed using Kapa SYBR Fast qPCR (Kapa Biosystems, Wilmington, MA, USA) and a StepOne real time PCR machine (Applied Biosystems, Grand Island, NY, USA). Primers used for PCR were as follows (F, forward; R, reverse): alkaline phosphatase (ALP), F GGAATACGAAC-TGGATGAGAAGG; ALP, R GGTTCCAGACATAGTGGGAATG ; osteocalcin (OCN), F CCAAGCAGGAGGGCAATA ; OCN, R AG-GGCAGCACAGGTCCTAA; Actin, F CCGTCAGGCAGCTCATA-GCTC; Actin, R GTCACCCACACTGTGCCCATC; hypoxanthine phosphoribosyltransferase, F TCCTCCTCAGACCGCTTTT; hypoxanthine phosphoribosyltransferase, R CCTGGTTCATCAGCGC-TAATC; bone sialoprotein (BSP), F CGGCCACGCTACTTTCTT-TA; BSP, R GAACTATCGCCGTCTCCATTT; EPO-R, F CCCCTC-TGTCTCCTACTT; EPO-R, R GTTGGGTGAAGCACAGAAGTT.
FACS analyses
To determine the cell distribution in bone marrow, cells flushed from 1 femur and red blood cells were lysed using ACK lysis buffer (Quality Biologic, Gaithersburg, MD, USA). Blocking was performed with 2% FBS. For cells in cultures, cells were detached with trypsin. Then, an aliquot of 1 3 10 6 cells was stained with labeled antibodies: allophycocyanin-conjugated antimouse M-CSF receptor (M-CSF-R, a.k.a. CD115 and CSF1-R); phycoerythrin-conjugated anti-mouse RANK (CD265) antibodies, FITC-conjugated anti-mouse TER119, phycoerythrinconjugated anti-mouse B220, FITC-conjugated anti-mouse CD3, and allophycocyanin-conjugated anti-mouse IgM (eBiosciences, San Diego, CA,USA). Cells were fixed with 1% paraformaldehyde and analyzed on a Gallios flow cytometer (Beckman Coulter, Brea, CA, USA; for cells from Tg6 vs. WT animals) and on a FACSort machine (BD Biosciences, San Jose, CA, USA; for cells from EPO-or diluent-injected animals).
Western blotting
Western blot was performed as previously described (33) . Briefly, preosteoclasts were seeded in 6-well plates with osteoclastogenic medium for 18 hours. Cells were then washed twice with PBS, and fresh medium with no supplements was added. EPO (10 U/ml) was added 60 or 10 minutes before cell lysis performed on ice. The antibodies for Erk and Phospho-Erk were from Santa Cruz Biotechnology, Santa Cruz, CA, USA; phospho-Jak2 and phospho-Akt were from Cell Signaling.
Statistical analysis
Values are expressed as means 6 SEM unless otherwise indicated. All statistical analyses were performed using IBM SPSS, version 21 software (IBM, Armonk, NY, USA). The Student t test (for 2 groups only) or ANOVA and Tukey's post hoc test (for multiple groups comparison) were used. Difference between groups was defined as P , 0.05.
RESULTS
Low bone mass phenotype in EPO-overexpressing mice
In view of the controversially reported effects of EPO in bone remodeling (27, 28, 30, 31, 41) , we first investigated the bone phenotype of mice constitutively overexpressing human EPO in an oxygen-independent manner (Tg6 mice). These mice are mainly characterized by excessive erythrocytosis and splenomegaly (34) and are used here as a model for pathophysiologic increase in the endogenous production of the hormone. EPO levels in the serum of Tg6 mice were ;29-fold higher than in WT (312.4 6 93.1 vs. 10.8 6 2.1 mU/ml, P , 0.0001, n = 8). mCT analysis of 12-week-old Tg6 female mice revealed a low bone mass phenotype compared with littermate controls (Fig. 1) . The trabecular bone fraction (BV/TV) measured in the distal femur metaphysis of Tg6 mice was 61% lower than in WT controls. This was associated with a reduction in trabecular number (Tb.N) and connectivity density (Conn.D), but not in the mean trabecular thickness. We also found that the bone loss was markedly greater in the proximal part of the distal metaphysis (2100% in BV/TV) compared with the distal part (261%) that is closer to the growth plate (Supplemental Fig. S1) . No difference was observed in the femoral length and middiaphyseal diameter, but both cortical thickness and moment of inertia were lower in the Tg6 animals ( Table 1) .
Increased bone resorption and reduced bone formation in EPO-overexpressing mice
In pursuit of the cellular mechanism underlying the low bone mass phenotype of Tg6 mice, we measured indicators of bone resorption and bone formation in vivo. First, we enumerated differentiated osteoclasts on trabecular bone surfaces using TRAP staining of histologic sections and found that Tg6 mice had a 25% higher osteoclast number per bone surface (N.Oc/BS) compared with WT controls ( Fig. 2A, B) . Further implicating bone resorption in this low bone mass phenotype, Tg6 mice exhibited a 28% increase in the serum levels of TRAP5b (Fig. 2C) , a biochemical marker of bone resorption.
Because previous reports suggested a possible role for EPO in cells of the osteoblast lineage (30, 41, 42) , we also tested whether the low bone mass phenotype in Tg6 mice was associated with reduced bone formation. We used vital double calcein labeling to assess bone matrix apposition in vivo. Although the mineralizing surface (MS/BS, a surrogate for osteoblast number) was not affected, serum OCN levels, mineral apposition rate (MAR, a surrogate for osteoblast activity), and overall bone formation rate (BFR/BS) were all reduced in the EPO-overexpressing animals ( Fig. 2D-G) .
EPO administration induces bone loss in adult mice
To assess the therapeutic effect of short-term intermittent administration of the hormone, we then investigated the effect of EPO injections on bone metabolism. In line with our findings on Tg6 mice, injections of low doses of rHuEPO (30U-inj) resulted in a significant trabecular bone loss (Fig. 3) . The trabecular bone fraction was 51% lower than in the diluent-injected controls. The microarchitectural changes were also similar to the Tg6 mice, showing a reduction in Tb.N (263%) and Conn.D (259%), whereas the mean thickness of the remaining trabeculae was slightly increased (+11%). Again, bone loss was markedly greater in the proximal part (295% in BV/TV) of the distal metaphysis compared with the distal part (251%; Supplemental Fig. S1 ), and no changes were observed in the femoral length (Table 1 ). In contrast with the Tg6 mice, short-term EPO administration did not affect the middiaphyseal diameter and cortical thickness ( Table 1 ). Of note, higher intermittently administered dosage of rHuEPO (180U-inj) resulted in a similar skeletal response, with 48% lower BV/TV, 62% lower Tb.N, 57% lower Conn.D, and 18% higher Tb.Th (Supplemental Fig. S2 ). EPO-induced bone loss was also independent of the administration mode, as continuous administration of 7 U/mouse per day for 10 days using subcutaneous pumps resulted in a similar skeletal effect with 31% decrease in BV/TV, 30% lower Tb.N, 32% lower Conn.D, and no significant change in Tb.Th (Supplemental Fig. S2 ).
EPO administration stimulates bone resorption and attenuates bone formation in vivo
Bone loss in EPO-injected and Tg6 mice was very similar; EPO treatment (30U-inj) resulted in an 88% increase in osteoclast number in vivo and an 18% increase in TRAP5b serum levels. Bone formation was also similarly affected (although to a lesser extend) with 13% lower MAR, 19% lower BFR, and no significant change in MS/BS and serum OCN (Fig. 4) . Overall, in both models (Tg6 and EPOinjected mice), EPO induced severe bone loss both by increasing bone resorption and by attenuating bone formation.
EPO stimulates the monocytic lineage in vivo
Using flow cytometry on bone marrow cells, we assessed the effect of EPO on cell differentiation in the monocytic lineage in vivo. Bone marrow cells were immunostained for M-CSF receptor (M-CSF-R, also known as CD115, CSF1R, or cFms) and RANK (also known as CD265 or TNFRSF11A). In both the Tg6 and EPO injection models, the monocytic lineage was vastly stimulated by EPO ( Fig.  5A, C) , with a higher number of M-CSF-R + /RANK 2 monocytes/macrophages and .2-fold increase in M-CSF-R + /RANK + preosteoclasts (43) .
EPO does not inhibit osteoblast activity in vitro
We next investigated the direct role of low doses of EPO on isolated bone cells. In osteoblast cultures derived from adult bone marrow, EPO-R expression increased with osteoblastic differentiation (Supplemental Fig. S3A ). Although EPO markedly inhibited osteoblastic bone formation in vivo, EPO treatment (10 U/ml) in isolated cultures did not inhibit osteoblast differentiation, activity, and RNA expression of the classic marker genes ALP, BSP, and OCN (Supplemental Fig. S3B-D) . Osteoblast proliferation was also not affected by EPO administration in vitro (Supplemental Fig. S3E ).
EPO stimulates osteoclastogenesis via Jak2 and PI3K signaling pathways in monocyte-derived cells
As in the osteoblastic lineage, EPO-R was expressed in bone marrow-derived preosteoclasts, yet its level decreased with osteoclastic differentiation (Fig. 6A) . In line with its in vivo effect on bone resorption (Fig. 4) , EPO administration significantly stimulated osteoclastogenesis in cultures of bone marrow-derived preosteoclasts (Fig. 6B) . To ensure that these cultures do not contain erythroid cells, we analyzed the cells using flow cytometry (Supplemental Fig. S4 ). Indeed, our preosteoclasts in vitro consist of a purified population of M-CSF-R + monocyte-derived cells virtually devoid of erythroid, B and T cells, thus supporting the notion of EPO-R signaling in preosteoclasts. Because it has been suggested that EPO impairs osteoclast function (30) , we also performed a pit resorption assay. We found that pit resorption area was increased in EPO-treated cultures (Fig. 6C) , and the ratio between resorption area (measured in calcium phosphate-coated wells) and TRAP + area (measured in parallel, uncoated wells) remained unaffected (Fig. 6D ). This suggests that EPO does not impair osteoclast resorbing activity. EPO also did not affect preosteoclast proliferation (Fig. 6E) .
We then investigated the signaling pathways involved in EPO stimulation of osteoclast differentiation. Because EPO-R signaling cascades include Jak2, PI3K, and MEK/ MAPK (41, 44) , we tested the activation of the Jak2, PI3K, and MEK/MAPK pathways by EPO using immunoblot analysis in RANKL-treated bone marrow-derived preosteoclasts. We detected the phosphorylation of Jak2 and Akt (downstream of PI3K) but not of ERK (a member of the MAPK pathway) 10 minutes after EPO administration (Fig. 6F ). We also specifically inhibited each pathway using AG490, LY294002, and U0126, respectively, and tested whether the effect of EPO was maintained in either condition. As expected from the activation of the corresponding pathways (Fig. 6F) , the stimulatory effect of EPO on osteoclast differentiation was abrogated by AG490 and LY294002 but was not affected by U0126 (Fig. 6G) . As a positive control, increased doses of RANKL in the presence of these inhibitors resulted in further stimulation of osteoclastogenesis, indicating that the absence of stimulation in AG490-and LY294002-treated culture is caused by specific blockade of EPO-R signaling. This indicates that EPO-R signaling stimulates osteoclastogenesis via JAK2 and PI3K but independently of the MAPK pathway.
DISCUSSION
Recent reports on nonhematopoietic functions of EPO mediated by nonerythroid cells emphasize the physiologic and therapeutic importance of a better understanding of Figure 6 . EPO stimulates osteoclastogenesis in vitro. A) EPO-R transcript expression on differentiating osteoclasts derived from bone marrow. B) TRAP staining (images and relative TRAP + area) of osteoclasts after 6 days of differentiation 6 EPO (10 U/ml). *P , 0.05 compared with controls, t test. C) Pit resorption area from osteoclasts cultured on calcium phosphate-coated wells 6 EPO (10 U/ml). D) Pit resorption per osteoclast area ratio (to assess resorption activity per cell) in parallel cultures as in C on calcium phosphate-coated and uncoated plastic wells. E) Bone marrow-derived preosteoclast proliferation measured by thiazolyl blue tetrazolium bromide assay after 3 days of culture 6 EPO (10 U/ml). F) Western blot of phosphorylated JAK2, AKT, and ERK, 10 and 60 minutes following EPO administration (10 U/ml) to preosteoclasts. Total ERK was used as loading control. G) Relative TRAP + area of osteoclasts after 6 days of differentiation 6 EPO (10 U/ml) with/without the indicated inhibitor; AG490 (AG, 1 mM), U0126 (U, 1 mM), and LY294002 (LY, 0.1 mM). Higher dose of RANKL (High RANKL, 100 ng/ml) was added to separate wells with the indicated inhibitors. Data are means 6 SEM. *P , 0.05 compared with controls, t test; n . 3. the systemic actions of EPO. The present study demonstrates a bone catabolic effect of rHuEPO using several adult mouse models, namely EPO overexpressing mice (Tg6), intermittent injections of low and high EPO dosage, and continuous administration of low doses. In Tg6 mice, the increase in EPO levels is similar to the stimulation of EPO at high altitude (45) . This model is also relevant for the pathophysiologic increase of endogenous EPO levels observed after bleeding/repeated phlebotomies without the confounding direct effect of hypoxia on bone cells (46) and in cases of paraneoplastic production of EPO (47) , thalassemia, and polycythemia vera (48) . On the other hand, the 30U-inj model is relevant for therapeutic administration of exogenous EPO (16, 18) . In all the models presented herein, higher EPO serum levels resulted in lower trabecular bone density, mainly because of lower trabecular number. Our in vivo data indicate that EPO induces bone resorption and attenuates bone formation, as well as stimulates monocyte-derived cells in the bone marrow. Stimulation of osteoclastogenesis and bone resorption is likely attributable to EPO-R activation of the Jak2 and PI3K pathways in osteoclast precursors and therefore seems to occur independently of erythropoietic effects in the bone marrow.
As a side note, there was a mild but statistically significant increase in trabecular thickness in the Tg6 and EPOinjected animals, compared with their respective controls, despite the dramatic bone loss (.50% decrease in BV/TV). A similar observation has been repeatedly made in age-induced bone loss, where the average Tb.Th remains unaltered or even increases, especially in female mice (49, 50) . This may be because of the occurrence of compensatory mechanisms aimed at strengthening the fewer trabeculae that were not lost. However, the attenuated bone formation in EPO overexpressing and injected animals does not support this conclusion. It seems more reasonable to assume that the increased Tb. Th is consequent to a statistical bias as demonstrated previously (51) . Briefly, in age-induced bone loss (decreased BV/TV and Tb.N), the increased bone resorption equally reduces the thickness of all trabeculae, leading to the clearance of the thinnest structures and thus increasing the percentage of the remaining thicker trabeculae. The increased Tb.Th would therefore not result from an actual trabecular thickening but rather reflect a statistical bias that averages only the remaining thicker trabeculae.
The stimulatory effect of EPO on osteoclastogenesis as reported herein is in line with previous reports (30, 52) . However, it has been suggested that osteoclasts induced by EPO are not active (30) . Here we assessed the boneresorbing potential of osteoclasts induced by EPO treatment in vitro and found that the increased osteoclastogenesis was associated with a significant increase in the pit formation (Fig. 6C, D) . The fact that in parallel cultures, the total pit resorption area per total TRAP + area remained unaffected indicates that activity per cell was not impaired by EPO. This is further supported by our in vivo data showing an overall increase in the bone resorption marker TRAP5b (Figs. 2 and 4) .
As mentioned above, past reports on the general effect of EPO on bone are controversial and have recently been addressed in a review (53) . Discrepancies may be attributed to skeletal site specificity, age, or bone regeneration vs. steady-state remodeling. Indeed, we (data herein) and others (31) have found that EPO induces a dramatic trabecular bone loss in long bones of adult mice, whereas others reported an opposite effect, namely increased bone mass in vertebrae of newborn mice and in several models of bone regeneration (27, 28, 30, 42, 54) . In growing female mice (4-8 weeks of age), we found that the effect of EPO was very similar to that observed in adult animals in both the femur and vertebrae, which is contradictory to an earlier report under similar experimental conditions (30) . Although this discrepancy in young animals remains to be elucidated, the differential effect of EPO in bone regeneration models vs. atraumatic remodeling may depend on the involvement of osteoblastic vs. osteoclastic EPO signaling. Our in vivo data indicate a reduced bone formation, whereas in vitro experiments failed to reveal any direct effect of EPO on osteoblast proliferation, differentiation, and activity at a dose of 10 U/ml ( Fig. 6; Supplemental Fig. S3 ). Nevertheless, expression of EPO-R on osteoblasts (Supplemental Fig. S3 ), upregulation of EPO-R expression by EPO administration in osteoblasts cultures (data not shown), and reports by others on in vitro stimulation of osteoblast differentiation at doses higher than 10 U/ml (41, 55) collectively suggest that EPO directly affects osteoblasts, although at a dose range different than that required to stimulate monocyte-derived cells. The common link between the several reports that proposed an anabolic role for osteoblastic EPO-R signaling (27, 28, 42, 54) is that EPO was administered following bone injury (bone regeneration) rather than steady-state bone homeostasis. It is therefore reasonable to assume that, under the former conditions, EPO promotes bone formation via direct activation of EPO-R signaling in osteoblasts, whereas it negatively regulates the latter by directly targeting the monocyte lineage and overall attenuating bone Figure 7 . Summary of putative pathways describing EPO action on bone metabolism. Our data suggest that the effect of EPO on bone can be mediated either (1) directly by stimulating osteoclastogenesis or (2) by inhibiting osteoblasts and bone formation via unknown intermediary. In vitro and in vivo data from others in different experimental conditions support the idea that (3) direct activation of EPO-R on osteoblasts stimulates osteogenesis. Our data also suggest that direct activation of EPO-R requires higher concentrations of EPO in osteoblasts than in osteoclasts. It is not unlikely that some in vivo findings result from the combination of two or three of these mechanisms of action.
formation. Whether EPO inhibits osteoblast function under physiologic conditions in vivo via indirect mechanisms or by direct binding to the osteoblastic EPO-R remains to be elucidated.
The controversy on the effects of EPO on bone in vivo has also been suggested to be dose dependent (53) . To examine this possibility, we used both low (30U-inj) and high (180U-inj) doses and found similar skeletal effects ( Fig. 3; Supplemental Fig. S2 ). We also compared continuous (Tg6 mice and EPO pumps) vs. intermittent (EPO injections) administration and found no differences between the treatment modalities ( Figs. 1 and 3 ; Supplemental Figs. S1 and S2). Of note, the skeletal effect of EPO was very similar between the Tg6 model ( Figs. 1 and 2) and EPO-injected mice ( Figs. 3 and 4) , not only at the structural (lower BV/TV and Tb.N) but also at the mechanistic level (increased N.Oc/BS and reduced MAR). These findings suggest that the skeletal effect of EPO is independent of dose and treatment modality.
Notably, a previous study traced EPO-R-expressing cells in mice and concluded that EPO-R is expressed only in the erythroid lineage (31) . However, not all lineages were tested as the cell sorting was limited to only a subset of cell types and differentiation stages (31) . Importantly, no data were shown for mature osteoblasts and preosteoclasts/ osteoclasts, in which we specifically found high EPO-R expression. Our results are supported by other published studies reporting EPO-R expression and/or EPO-induced intracellular signaling in monocyte-derived and osteoblastic cells, as well as functional assays on isolated cultures that responded to EPO treatment (30, 33, 41, 55) . Still, we acknowledge the importance of investigating further this important question using specific anti-EPO-R antibodies and conditional knockout animal models currently under development.
Collectively, our in vivo and in vitro data, together with findings from others, suggest that the skeletal effect of EPO may be mediated by 3 different pathways (Fig. 7) . First, direct stimulation of EPO-R on osteoclast precursors stimulates osteoclastogenesis and promotes bone resorption; second, EPO inhibits osteoblastic bone formation in vivo, likely via indirect mechanisms; and third, data reported by others (27, 28, 30, 41, 42, 54, 55 ) support the idea that in different experimental conditions the predominant pathway is the direct activation of EPO-R on osteoblasts resulting in increased osteogenesis. In our in vivo models, bone loss may be attributed to both the first and second pathways. It is still reasonable to assume that the third pathway is also activated; namely, direct EPO-R signaling in osteoblasts stimulates osteoblastic proliferation and function, but it only partially antagonizes the systemic attenuation of osteoblastic bone formation (pathway 3 vs. 2; Fig. 7) .
Because of the prenatal lethality of EPO-R knockout mice and the unavailability of strong EPO-R antagonists, we could not test the effect of normal EPO levels by abrogating EPO-R signaling in vivo. Based on the conclusions of the present study, development of osteoclast-and osteoblastspecific conditional EPO-R knockout mice should be considered. We also acknowledge that our conclusions are mainly based on experimental data that will need to be verified in clinical settings. Although we could not find any direct evidence linking EPO to bone loss in humans, it has been established that exposure to high altitude lead to elevated levels of EPO (45, 56, 57) , and reports have shown that even short-term periods at high altitude (or simulated altitude) result in significant bone loss (58, 59) . In line with our conclusions, these observations provide evidence that high levels of EPO promote bone resorption in humans and suggest that the effect of hypoxia on bone metabolism is at least partly mediated by EPO-R signaling in the monocytic lineage.
